Pre-filled pen of Risankizumab medication. Marketed as Skyrizi, Risankizumab is a humanised monoclonal antibody that binds to interleukin 23A (IL-23A) and blocks the activity of pro-inflammatory cytokines. Risankizumab is used to treat moderate to severe plaque psoriasis and active psoriatic arthritis. It is administered by a subcutaneous injection. | |
Lizenzart: | Lizenzpflichtig |
Credit: | Science Photo Library / Marazzi, Dr. P. |
Bildgröße: | 6048 px × 4024 px |
Modell-Rechte: | nicht erforderlich |
Restrictions: |
|